Zeto, Inc. is a medical technology company developing wearable EEG (electroencephalography) headsets and a cloud-based platform to modernize brain monitoring for healthcare providers. It serves hospitals, clinics, ICUs, emergency departments, physician offices, and home settings, solving the problems of traditional EEG's complexity, preparation time, and limited accessibility by offering zero-prep, wireless devices with AI-driven seizure detection, remote neurologist interpretation, and video monitoring[1][2][5]. Zeto targets conditions like epilepsy, seizures, stroke, depression, and traumatic brain injury, with strong growth evidenced by its ranking on the 2024 Inc. 5000 list of America's fastest-growing private companies, FDA clearances in 2018 and 2024 for products like Zeto ONE, and a $31 million Series B funding round in January 2025 that brings total funding to $38.3 million[1][2][3].
Founded in 2014 in Santa Clara, California, by Aswin Gunasekar, who serves as CEO, Zeto emerged to address the outdated, labor-intensive nature of traditional EEG procedures requiring skin abrasion, conductive paste, and wired setups[2][4]. Gunasekar's vision was to transform EEG into a 21st-century solution using revolutionary FDA-cleared wireless headsets and cloud technology, initially focusing on hospitals and clinics[1][2]. Early traction came from FDA clearance in 2018, followed by pivotal milestones like the 2024 launch of next-generation Zeto ONE (cleared for hospital, home, ambulance, and air transport use) and rapid adoption by U.S. healthcare institutions, culminating in the 2025 Series B funding led by MindWorks Global[1][3].
Zeto stands out in EEG monitoring through these key advantages:
Zeto rides the wave of AI-driven medtech and telehealth expansion, capitalizing on post-pandemic demand for remote, accessible diagnostics amid neurologist shortages and rising neurological disorder prevalence (e.g., epilepsy affects millions)[1][3][5]. Timing aligns with FDA's support for innovative wearables, enabling EEG in non-traditional settings like homes and ambulances, which reduces patient transfers and hospital burdens[1][2][5]. Market forces favoring Zeto include a massive untapped potential in outpatient/home monitoring and AI for early detection, positioning it to influence ecosystem shifts toward decentralized neurocare and better outcomes in critical conditions[1][3].
Zeto's trajectory points to accelerated commercialization post-$31M Series B, with plans to scale sales teams, R&D for expanded AI detections (e.g., depression, TBI), and deeper healthcare partnerships[3]. Trends like AI diagnostics, wearable medtech, and value-based care will propel growth, potentially evolving Zeto into a dominant player in noninvasive brain health as adoption surges in underserved areas. This builds on its Inc. 5000 momentum, redefining EEG from a cumbersome test to an always-on, accessible vital sign[1][3].
Zeto has raised $7.0M in total across 1 funding round.
Zeto's investors include Foothill Ventures (formerly Tsingyuan Ventures), Quest Venture Partners, Maarten 't Hooft.
Zeto has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $7.0M Series A | Foothill Ventures (formerly Tsingyuan Ventures), Quest Venture Partners, Maarten 't Hooft |
